Contact Activation in Low‐density Lipoprotein Apheresis Systems
- 5 January 2005
- journal article
- Published by Wiley in Artificial Organs
- Vol. 29 (1), 47-52
- https://doi.org/10.1111/j.1525-1594.2004.29007.x
Abstract
Background: Anaphylactoid reactions due to contact activation have been observed in patients on ACE inhibitor therapy and hemodialysis with negatively charged dialysis membranes. Negatively charged surfaces are functional constituents of different LDL apheresis systems. Therefore, contact activation was investigated during LDL apheresis with three different systems: (i) heparin‐induced extracorporeal LDL precipitation (HELP); (ii) dextran sulfate cellulose (DSC) columns; and (iii) modified polyacrylate gels (DALI) in a clinical setting. Methods: 24 prevalent patients on regular LDL apheresis treatment were included in the study. Bradykinin, prekallikrein, and HMW kininogen were measured during a single LDL apheresis at different sites of the systems. Results: LDL apheresis with DSC and DALI was associated with an extreme release of bradykinin after the passage of plasma or blood through the LDL adsorbers as well as with a decrease of prekallikrein and HMW kininogen during the course of the treatment. Bradykinin release exceeded the degradation capacity of the kininase II, since markedly elevated bradykinin concentrations were observed in the arterial line of the extracorporeal circuits of both systems. This was not associated with anaphylactoid reactions. In contrast to the treatments with DSC and DALI, the HELP system did not lead to any activation of the kallikrein–kinin system. Conclusion: From our data we conclude that angiotensin converting enzyme (ACE) inhibitors are contraindicated in patients on LDL apheresis with the DSC and the DALI system. Because the HELP system does not activate the kallikrein–kinin system, patients who need ACE inhibitors are predisposed for this LDL apheresis procedure.Keywords
This publication has 21 references indexed in Scilit:
- Anaphylactoid reactions during hemodialysis in sheep are ACE inhibitor dose-dependent and mediated by bradykininKidney International, 1998
- Current status of low density lipoprotein-apheresis for the therapy of severe hyperlipidemiaCurrent Opinion in Lipidology, 1996
- Low–Density Lipoprotein Hemoperfusion Using a Modified Polyacrylate Adsorber: In Vitro, Ex Vivo, and First Clinical ResultsArtificial Organs, 1996
- The HELP‐LDL‐apheresis multicentre study, an angiographically assessed trial on the role of LDL‐apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL‐cholesterol plasma concentrations and the course of coronary heart disease*European Journal of Clinical Investigation, 1994
- Prevention with icatibant of anaphylactoid reactions to ACE inhibitor during LDL apheresisThe Lancet, 1994
- Anaphylactoid Reactions and Bradykinin Generation in Patients Treated with LDL-Apheresis and an ACE InhibitorASAIO Journal, 1993
- Anaphylactoid reactions, LDL apheresis with dextran sulphate, and ACE inhibitorsThe Lancet, 1992
- Effects of angiotensin II on pressor responses to norepinephrine in humansLife Sciences, 1991
- Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitorsKidney International, 1990
- Possible basis for the apparent surface selectivity of the contact activation of human blood coagulation factor XIIBiochemistry, 1986